Tissue specific stem cell therapy for airway regeneration

Abstract

Secondary atrophic rhinitis (AR), a consequence of mucosal damage during nasal surgeries, significantly impairs patient quality of life. The lack of effective, lasting treatments underscores the need for alternative therapeutic strategies. A major impediment in advancing research is the scarcity of studies focused on secondary AR. Our study addresses this gap by developing an animal model that closely mirrors the histopathological changes observed in patients with secondary AR. These changes include squamous metaplasia, goblet cell hyperplasia, submucosal fibrosis, and glandular atrophy. Upon administering human nasal turbinate stem cells embedded in collagen type I hydrogel in these models, we observed ciliary regeneration. This finding suggests the potential therapeutic benefit of this approach. Our animal models not only emulate the clinical manifestations of secondary AR but also serve as valuable tools for evaluating the efficacy of cell-based biotechnological interventions.

References

[1] ParkSC, KimDH, JunYJ, et al. Long-term outcomes of turbinate surgery in patients with allergic rhinitis: a systematic review and meta-analysis. JAMA Otolaryngol Head Neck Surg. 2023;149:15-23.

[2] AndersonM, LiangJ. Trends in inferior turbinate surgery: analysis of patients using the Medicare database. Int Forum Allergy Rhinol. 2018;8:1169-1174.

[3] PassàliD, Lauriello M, AnselmiM, BellussiL. Treatment of hypertrophy of the inferior turbinate: long-term results in 382 patients randomly assigned to therapy. Ann Otol Rhinol Laryngol. 1999;108:569-575.

[4] ChhabraN, HouserSM. The diagnosis and management of empty nose syndrome. Otolaryngol Clin N Am. 2009;42(2):311-330.

[5] CosteA, DessiP, SerranoE. Empty nose syndrome. Eur Ann Otorhinolaryngol Head Neck Dis. 2012;129:93-97.

[6] ScheithauerMO. Surgery of the Turbinates and “Empty Nose” Syndrome. GMS Curr Top Otorhinolaryngol Head Neck Surg. 2010;9:Doc03.

[7] GillAS, SaidM, TollefsonTT, Steele TO. Update on empty nose syndrome: disease mechanisms, diagnostic tools, and treatment strategies. Curr Opin Otolaryngol Head Neck Surg. 2019;27:237-242.

[8] LiC, FaragAA, MazaG, et al. Investigation of the abnormal nasal aerodynamics and trigeminal functions among empty nose syndrome patients. Int Forum Allergy Rhinol. 2018;8:444-452.

[9] MishraA, Kawatra R, GolaM. Interventions for atrophic rhinitis. Cochrane Database Syst Rev. 2012;15(2):Cd008280.

[10] GordiienkoIM, GubarOS, SulikR, Kunakh T, ZlatskiyI, ZlatskaA. Empty nose syndrome pathogenesis and cell-based biotechnology products as a new option for treatment. World J Stem Cells. 2021;13:1293-1306.

[11] MagyarT, KingV, KovacsF. Evaluation of vaccines for atrophic rhinitis—a comparison of three challenge models. Vaccine. 2002;20:1797-1802.

[12] Michael HerfsPH, Poirrier A-L, VandevenneP, et al. Proinflammatory cytokines induce bronchial hyperplasia and squamous metaplasia in smokers: implications for chronic obstructive pulmonary disease therapy. Am J Respir Cell Mol Biol. 2012;47:67-79.

[13] KatoT, Hikichi T, NakamuraJ, et al. Association between submucosal fibrosis and endoscopic submucosal dissection of recurrent esophageal squamous cell cancers after Chemoradiotherapy. Cancers (Basel). 2022;14:14.

[14] Sherwin VRRP, Everson RB, RichtersA. Chronic glandular bronchitis in young individuals residing in a metropolitan area. Virchows Arch. 1998;433:341-348.

[15] AndrewT, ReidPCV, GosensR, et al. Persistent induction of goblet cell differentiation in the airways: therapeutic approaches. Pharmacol Therap. 2018;185:155-169.

[16] Asma YaghiMBD. Airway epithelial cell cilia and obstructive lung disease. Cells. 2016;5(4):40.

[17] MooreEJ, KernEB. Atrophic rhinitis: a review of 242 cases. Am J Rhinol. 2001;15:355-361.

[18] HoriguchiY. Swine atrophic rhinitis caused by Pasteurella multocida toxin and Bordetella dermonecrotic toxin. Pasteurella Multocida: Molecular Biology, Toxins and Infection. 2012;361:113-129.

[19] WuCL, FuCH, LeeTJ. Distinct histopathology characteristics in empty nose syndrome. Laryngoscope. 2021;131:E14-E18.

[20] SumailyIA, HakamiNA, AlmutairiAD, et al. An updated review on atrophic rhinitis and empty nose syndrome. Ear Nose Throat J. 2023;14:01455613231185022.

[21] MalikJ, Thamboo A, DholakiaS, et al. The cotton test redistributes nasal airflow in patients with empty nose syndrome. Int Forum Allergy Rhinol. 2020;10:539-545.

[22] LeongSC. The clinical efficacy of surgical interventions for empty nose syndrome: a systematic review. Laryngoscope. 2015;125:1557-1562.

[23] MoonBJ, LeeHJ, JangYJ. Outcomes following rhinoplasty using autologous costal cartilage. Arch Facial Plast Surg. 2012;14:175-180.

[24] JaswalA, JanaAK, SikderB, Nandi TK, SadhukhanSK, DasA. Novel treatment of atrophic rhinitis: early results. Eur Arch Otorhinolaryngol. 2008;265:1211-1217.

[25] KimDH, LeeMH, LeeJ, SongEA, KimSW, Kim SW. Platelet-rich plasma injection in patients with atrophic rhinitis. ORL J Otorhinolaryngol Relat Spec. 2021;83:104-111.

[26] KimDY, HongHR, ChoiEW, Yoon SW, JangYJ. Efficacy and safety of autologous stromal vascular fraction in the treatment of empty nose syndrome. Clin Exp Otorhinolaryngol. 2018;11:281-287.

[27] UmS-H, SeoY, SeoH, et al. Biomimetic hydrogel blanket for conserving and recovering intrinsic cell properties. Biomater Res. 2022;26:1-15.

[28] Sung Won KimJHC, HongMW, RhieJ-W, Yoon HR. Induction of chondrogenic differentiation in cultured fibroblasts isolated from the inferior turbinate. Otolaryngol Head Neck Surg. 2008;139:143-148.

[29] LimJY. Potential application of human neural crest-derived nasal turbinate stem cells for the treatment of neuropathology and impaired cognition in models of Alzheimer’s disease. Stem Cell Res Ther. 2021;12:402.

[30] KimC-S. The ability of human nasal inferior turbinate–derived mesenchymal stem cells to repair vocal fold injuries. Otolaryngology–Head and Neck Surgery. 2018;159(2):335-342.

[31] HesseE. Collagen type I hydrogel allows migration, proliferation and osteogenic differentiation of rat bone marrow stromal cells. J Biomed Mater Res A. 2010;94A:442-449.

[32] SimorghS. Human olfactory mucosa stem cells delivery using a collagen hydrogel: As a potential candidate for bone tissue engineering. Materials. 2021;14(14):3909.

[33] XuX. Conductive collagen-based hydrogel combined with electrical stimulation to promote neural stem cell proliferation and differentiation. Front Bioeng Biotechnol. 2022;10:912497.

[34] BesussoD. Stem cell-derived human striatal progenitors innervate striatal targets and alleviate sensorimotor deficit in a rat model of Huntington disease. Stem Cell Rep. 2020;14:876-891.

[35] SunL, WangF, ChenH, et al. Co-transplantation of human umbilical cord mesenchymal stem cells and human neural stem cells improves the outcome in rats with spinal cord injury. Cell Transplant. 2019;28:893-906.

[36] Yu-ShowFu C-FCea. Xenograft of human umbilical mesenchymal stem cells from Wharton’s jelly differentiating into osteocytes and reducing osteoclast activity reverses osteoporosis in Ovariectomized rats. Cell Transplant. 2018;27(1):194-208.

[37] Labrador-VelandiaS. Mesenchymal stem cells provide paracrine neuroprotective resources that delay degeneration of co-cultured organotypic neuroretinal cultures. Exp Eye Res. 2019;185:107671.

[38] QuanhuGE, ZhangH, HouJ, et al. VEGF secreted by mesenchymal stem cells mediates the differentiation of endothelial progenitor cells into endothelial cells via paracrine mechanisms. Mol Med Rep. 2018;17(1):1667-1675.

[39] Jin Seon KwonSWK, Kwon DY, ParkSH, Reum SonA, KimJH, KimMS. In vivo osteogenic differentiation of human turbinate mesenchymal stem cells in an injectable in situ-forming hydrogel. Biomaterials. 2014;35:5337-5346.

RIGHTS & PERMISSIONS

2024 The Authors. Cell Proliferation published by Beijing Institute for Stem Cell and Regenerative Medicine and John Wiley & Sons Ltd.